The B Cell Biology Scientific Research Support Component (SRSC) will assist in the generation of novel vaccines that target broad neutralizing antibodies (BnAbs) or other protective B-cell precursors by B lineage immunogen design. The novel vaccines generated by the CHAVI-ID B Cell Focus will be designed to activate the unmutated ancestors (UA) of highly mutated BnAb B cells isolated by flow cytometry. As a parallel strategy, this B Cell Biology SRSC will first isolate human B-cell precursors, and drives their maturation in vitro. BnAb precursors will then be identified and allowed to proliferate, mature and undergo Ig class-switching (CSR) in vitro. In this manner, the B Cell Biology SRSC will complement the work of the B Lineage Immunogen Design teams by identifying and selecting BnAb precursors -unmutated ancestors B cells - that are comparable to, and possibly better than, those inferred from BnAb clonal lineages. This support component will identify, isolate, characterize, and activate de novo B cells capable of generating BnAb responses, allowing the direct study of BnAb UA and intermediate antibody (IA) B cells.
Specific Aims Aim 1. Culture Env-specific immature B cells from human bone marrow in vitro and drive them to express AID and undergo Ig class-switch recombination in vitro to characterize BnAb maturation pathways.
Aim 2. Culture Env-specific immature B cells from humanized Velocimmune? mice in vitro and drive antigen-specific B cells to compete and mature by AID expression and Ig CSR to characterize BnAb maturation pathways.
Aim 3. Immunize immunoglobulin humanized mice with candidate Env vaccines to determine their immunogenicity by characterizing serum antibody responses and hybridoma lines.
This support component will grow human and immunoglobulin humanized mouse B cells in test tubes and these will be used to identify candidate HlV-1 vaccine antigens. This approach will allow novel molecular vaccine designs to be tested inexpensively, rapidly, and ethically.
|Winawer, Melodie R; Griffin, Nicole G; Samanamud, Jorge et al. (2018) Somatic SLC35A2 variants in the brain are associated with intractable neocortical epilepsy. Ann Neurol 83:1133-1146|
|Dong, Yuanchen; Chen, Shuobing; Zhang, Shijian et al. (2018) Folding DNA into a Lipid-Conjugated Nanobarrel for Controlled Reconstitution of Membrane Proteins. Angew Chem Int Ed Engl 57:2072-2076|
|Prévost, Jérémie; Richard, Jonathan; Medjahed, Halima et al. (2018) Incomplete Downregulation of CD4 Expression Affects HIV-1 Env Conformation and Antibody-Dependent Cellular Cytotoxicity Responses. J Virol 92:|
|Prévost, Jérémie; Richard, Jonathan; Ding, Shilei et al. (2018) Envelope glycoproteins sampling states 2/3 are susceptible to ADCC by sera from HIV-1-infected individuals. Virology 515:38-45|
|Saunders, Kevin O; Santra, Sampa; Parks, Robert et al. (2018) Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates. J Virol 92:|
|Wu, Helen L; Wiseman, Roger W; Hughes, Colette M et al. (2018) The Role of MHC-E in T Cell Immunity Is Conserved among Humans, Rhesus Macaques, and Cynomolgus Macaques. J Immunol 200:49-60|
|Wiehe, Kevin; Bradley, Todd; Meyerhoff, R Ryan et al. (2018) Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development. Cell Host Microbe 23:759-765.e6|
|Cheng, Hao D; Grimm, Sebastian K; Gilman, Morgan Sa et al. (2018) Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site. JCI Insight 3:|
|Castillo-Menendez, Luis R; Witt, Kristen; Espy, Nicole et al. (2018) Comparison of Uncleaved and Mature Human Immunodeficiency Virus Membrane Envelope Glycoprotein Trimers. J Virol 92:|
|Brown, Eric P; Weiner, Joshua A; Lin, Shu et al. (2018) Optimization and qualification of an Fc Array assay for assessments of antibodies against HIV-1/SIV. J Immunol Methods 455:24-33|
Showing the most recent 10 out of 261 publications